[Multiple myeloma]
Ramón García-Sanz1, María Victoria Mateos, Jesús Fernando San Miguel
1Servicio de Hematología, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Salamanca, España. rgarcias@usal.es
Medicina Clinica
|June 28, 2007
Summary
Multiple myeloma, a common blood cancer, is increasingly manageable with new therapies and supportive care, significantly improving patient survival and quality of life.
Area of Science:
- Hematological Malignancies
- Oncology
- Plasma Cell Disorders
Context:
- Multiple myeloma is the second most common hematological malignancy.
- Characterized by monoclonal plasma cells producing paraproteins, leading to anemia, renal insufficiency, hypercalcemia, and bone lesions.
- Advances in understanding chromosomal and molecular abnormalities aid in disease management.
Purpose:
- To review recent advancements in the treatment and supportive care of multiple myeloma.
- To highlight the impact of novel therapies and supportive measures on patient outcomes.
- To provide an overview of current clinical experience in managing multiple myeloma.
Summary:
- Emergence of new therapies including thalidomide, lenalidomide, and bortezomib over the last six years.
- Significant improvements in patient prognosis and quality of life, with median survival exceeding five years.
- Enhancements in supportive care, such as dialysis, erythropoietin stimulating agents, bisphosphonates, vertebroplasty, and kyphoplasty.
Impact:
- Improved patient survival and quality of life in multiple myeloma.
- Potential for further advancements beyond standard autologous stem cell transplantation.
- Demonstrates the evolving landscape of multiple myeloma treatment and care.
